Innovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 Million

Preliminary Annual Revenue Increase by 2.7x Compared to Prior Year

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”)
(OTCQB: INNV) today announced preliminary annual 2018 net revenue is
estimated to be $24.0 million or approximately 2.7x the annual 2017 net
revenue of $8.8 million. Innovus Pharma’s annual 2018 anticipated net
revenue results are preliminary and based on the most current
information available and are subject to completion of the audited
consolidated financial statements for the year ended December 31, 2018,
which are to be filed with the Securities and Exchange Commission (“SEC”)
as part of the Company’s Annual Report on Form 10-K (“Annual Report”)
no later than April 1, 2019. Actual results may differ from the
preliminary results reported herein. Investors are encouraged to review
the Company’s Annual Report when filed with the SEC.

“We are very happy with the increased growth in our sales channels,
additional markets and product pipeline with our estimated annual 2018
net revenue of $24.0 million, which is in line with what we previously
projected,” stated Bassam Damaj, President and Chief Executive Officer
of Innovus Pharma. “We continue to work hard towards our operational and
financial goals to increase the breadth of our product offerings and
work to achieve potential profitability.”